TALEN

TALEN1-mettl3

ID
ZDB-TALEN-180302-2
Name
TALEN1-mettl3
Previous Names
None
Target
Target Sequence 1
5' - CATCCAGGCGCACAA - 3'
ZFIN BLAST NCBI BLAST Ensembl
Target Sequence 2
5' - GCAGCCTCTCTCGTAGT - 3'
ZFIN BLAST NCBI BLAST Ensembl
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
ihb306 mettl3
ihb307 mettl3
Expression
Gene expression in Wild Types + TALEN1-mettl3
No data available
Phenotype
Phenotype resulting from TALEN1-mettl3
No data available
Phenotype of all Fish created by or utilizing TALEN1-mettl3
Phenotype Fish Conditions Figures
ovary has fewer parts of type ovarian follicle stage IV, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 4 from Xia et al., 2017
testis lacks parts or has fewer parts of type sperm, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 6 from Xia et al., 2017
whole organism dead, abnormal mettl3ihb306/ihb306 (AB) standard conditions text only from Xia et al., 2017
testis hsd17b3 expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
female organism ovulation decreased rate, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 8 from Xia et al., 2017
testis mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity decreased occurrence, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 3 from Xia et al., 2017
female organism decreased female fertility, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 8 from Xia et al., 2017
ovarian follicle stage IV igf3 expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
whole organism brood viability, abnormal mettl3ihb306/ihb306 (AB) standard conditions text only from Xia et al., 2017
brain mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity decreased occurrence, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 3 from Xia et al., 2017
testis has extra parts of type spermatocyte, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 6 from Xia et al., 2017
testis hsd3b2 expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
testis star expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
male organism hypophysis fshb expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
flagellated sperm motility decreased process quality, abnormal mettl3ihb306/ihb306 (AB) standard conditions text only from Xia et al., 2017
ovary decreased size, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 4 from Xia et al., 2017
oocyte stage IV meiosis II nuclear membrane disassembly disrupted, ameliorated mettl3ihb306/ihb306 (AB) chemical treatment: Chorionic gonadotropin Fig. 5 from Xia et al., 2017
muscle mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity decreased occurrence, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 3 from Xia et al., 2017
whole organism viability, abnormal mettl3ihb306/ihb306 (AB) standard conditions text only from Xia et al., 2017
testis has extra parts of type spermatogonium, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 6 from Xia et al., 2017
testis cyp17a1 expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
female organism ratio male organism, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 8 from Xia et al., 2017
liver mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity decreased occurrence, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 3 from Xia et al., 2017
testis cyp11a1.1 expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
oocyte stage IV oocyte maturation disrupted, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 5 from Xia et al., 2017
female organism has fewer parts of type oocyte stage V, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 8 from Xia et al., 2017
testis decreased size, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 6 from Xia et al., 2017
ovarian follicle stage IV pgr expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
blood 11-oxotestosterone decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 10 from Xia et al., 2017
oocyte stage IV meiosis II nuclear membrane disassembly disrupted, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 5 from Xia et al., 2017
ovarian follicle stage IV star expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
testis fshr expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
ovarian follicle stage IV fsta expression increased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
female organism hypophysis lhb expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
ovarian follicle stage IV cyp19a1a expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
oocyte stage IV meiosis II nuclear membrane disassembly disrupted, ameliorated mettl3ihb306/ihb306 (AB) chemical treatment by injection: (20R)-17,20-dihydroxypregn-4-en-3-one Fig. 5 from Xia et al., 2017
blood estradiol decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 10 from Xia et al., 2017
sex determination process quality, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 8 from Xia et al., 2017
testis cyp17a2 expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
ovary mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity decreased occurrence, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 3 from Xia et al., 2017
ovarian follicle stage IV hsd3b2 expression decreased amount, abnormal mettl3ihb306/ihb306 (AB) standard conditions Fig. 9 from Xia et al., 2017
female organism ovulation decreased rate, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 8 from Xia et al., 2017
testis hsd17b3 expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
ovary has fewer parts of type ovarian follicle stage IV, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 4 from Xia et al., 2017
female organism decreased female fertility, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 8 from Xia et al., 2017
testis lacks parts or has fewer parts of type sperm, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 6 from Xia et al., 2017
testis hsd3b2 expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
whole organism brood viability, abnormal mettl3ihb307/ihb307 (AB) standard conditions text only from Xia et al., 2017
testis mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity decreased occurrence, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 3 from Xia et al., 2017
whole organism dead, abnormal mettl3ihb307/ihb307 (AB) standard conditions text only from Xia et al., 2017
ovarian follicle stage IV igf3 expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
brain mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity decreased occurrence, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 3 from Xia et al., 2017
testis has extra parts of type spermatocyte, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 6 from Xia et al., 2017
male organism hypophysis fshb expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
testis star expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
flagellated sperm motility decreased process quality, abnormal mettl3ihb307/ihb307 (AB) standard conditions text only from Xia et al., 2017
ovary decreased size, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 4 from Xia et al., 2017
muscle mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity decreased occurrence, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 3 from Xia et al., 2017
oocyte stage IV meiosis II nuclear membrane disassembly disrupted, ameliorated mettl3ihb307/ihb307 (AB) chemical treatment: Chorionic gonadotropin Fig. 5 from Xia et al., 2017
whole organism viability, abnormal mettl3ihb307/ihb307 (AB) standard conditions text only from Xia et al., 2017
testis has extra parts of type spermatogonium, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 6 from Xia et al., 2017
testis cyp17a1 expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
blood 11-oxotestosterone decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 10 from Xia et al., 2017
testis cyp11a1.1 expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
female organism ratio male organism, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 8 from Xia et al., 2017
oocyte stage IV oocyte maturation disrupted, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 5 from Xia et al., 2017
female organism has fewer parts of type oocyte stage V, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 8 from Xia et al., 2017
liver mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity decreased occurrence, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 3 from Xia et al., 2017
testis decreased size, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 6 from Xia et al., 2017
ovarian follicle stage IV pgr expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
oocyte stage IV meiosis II nuclear membrane disassembly disrupted, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 5 from Xia et al., 2017
ovarian follicle stage IV star expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
sex determination process quality, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 8 from Xia et al., 2017
ovarian follicle stage IV cyp19a1a expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
testis fshr expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
oocyte stage IV meiosis II nuclear membrane disassembly disrupted, ameliorated mettl3ihb307/ihb307 (AB) chemical treatment by injection: (20R)-17,20-dihydroxypregn-4-en-3-one Fig. 5 from Xia et al., 2017
testis cyp17a2 expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
ovarian follicle stage IV hsd3b2 expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
blood estradiol decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 10 from Xia et al., 2017
female organism hypophysis lhb expression decreased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
ovary mRNA (2'-O-methyladenosine-N6-)-methyltransferase activity decreased occurrence, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 3 from Xia et al., 2017
ovarian follicle stage IV fsta expression increased amount, abnormal mettl3ihb307/ihb307 (AB) standard conditions Fig. 9 from Xia et al., 2017
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.